Twinbeech Capital LP Inhibrx, Inc. Transaction History
Twinbeech Capital LP
- $4.66 Billion
- Q1 2024
Shares
1 transactions
Others Institutions Holding INBX
# of Institutions
132Shares Held
35.5MCall Options Held
64.8KPut Options Held
91.3K-
Viking Global Investors LP7.15MShares$101 Million0.95% of portfolio
-
Perceptive Advisors LLC New York, NY4.26MShares$60.3 Million3.12% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$39 Million0.0% of portfolio
-
State Street Corp Boston, MA2.42MShares$34.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$26.4 Million0.0% of portfolio
About Inhibrx, Inc.
- Ticker INBX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,057,700
- Market Cap $553M
- Description
- Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...